SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| O'Day Daniel Patrick | Chairman & CEO, Director | 2026-09-01 | Open-market sell 10b5-1 | 1600 | $236K |
| O'Day Daniel Patrick | Chairman & CEO, Director | 2026-09-01 | Open-market sell 10b5-1 | 7992 | $1.2M |
| O'Day Daniel Patrick | Chairman & CEO, Director | 2026-09-01 | Open-market sell 10b5-1 | 5408 | $808K |
| WELTERS ANTHONY | Director | 2026-08-26 | Option exercise 10b5-1 | 7718 | $468K |
| WELTERS ANTHONY | Director | 2026-08-26 | Open-market sell 10b5-1 | 3118 | $462K |
| WELTERS ANTHONY | Director | 2026-08-26 | Open-market sell 10b5-1 | 4600 | $685K |
| WELTERS ANTHONY | Director | 2026-08-26 | Option exercise 10b5-1 | 10282 | $631K |
| WELTERS ANTHONY | Director | 2026-08-26 | Open-market sell 10b5-1 | 3402 | $504K |
| WELTERS ANTHONY | Director | 2026-08-26 | Open-market sell 10b5-1 | 6880 | $1.0M |
| Bluestone Jeffrey | Director | 2026-08-20 | Option exercise 10b5-1 | 1165 | $79K |
| Bluestone Jeffrey | Director | 2026-08-20 | Open-market sell 10b5-1 | 1165 | $167K |
| Bluestone Jeffrey | Director | 2026-08-20 | Option exercise 10b5-1 | 1816 | $122K |
| Bluestone Jeffrey | Director | 2026-08-20 | Open-market sell 10b5-1 | 1816 | $263K |
| Bluestone Jeffrey | Director | 2026-08-20 | Option exercise 10b5-1 | 1658 | $112K |
| Bluestone Jeffrey | Director | 2026-08-20 | Open-market sell 10b5-1 | 1658 | $242K |
| Bluestone Jeffrey | Director | 2026-08-20 | Option exercise 10b5-1 | 26 | $2K |
| Bluestone Jeffrey | Director | 2026-08-20 | Open-market sell 10b5-1 | 26 | $4K |
| Bluestone Jeffrey | Director | 2026-08-20 | Option exercise 10b5-1 | 335 | $21K |
| Bluestone Jeffrey | Director | 2026-08-20 | Open-market sell 10b5-1 | 335 | $49K |
| Dickinson Andrew D | Chief Financial Officer | 2026-08-17 | Open-market sell 10b5-1 | 3000 | $415K |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
Regulatory and operational risk expanded materially across multiple fronts, led by Medicare drug-price negotiation for Biktarvy, new Medicaid/tariff/MFN pricing pressures, FDA capacity constraints, and a $32B domestic manufacturing commitment carrying significant execution risk. A Phase 3 failure for Trodelvy (ASCENT-07) introduces a concrete impairment threat to a key growth asset, while newly disclosed supply-chain dependencies and BIOSECURE Act exposure add geopolitical fragility. Two easing items — REMS expiry for Yescarta/Tecartus and ERP completion — are real but modest offsets against a broadly worsening picture.
6 company-specific · 2 eased/removed · 2 common-mode
Newly disclosed $32B multi-year U.S. manufacturing/R&D investment with material execution risks: delays, cost inflation, regulatory compliance, skilled labor constraints, and potential asset impairments.
Our U.S. manufacturing and R&D investments may not achieve their intended benefits and could adversely affect our business, results of operations and cash flows. We are undertaking significant…
Multiple new material regulatory and pricing risks: Biktarvy selected for Medicare negotiation (2028), OBBB Act Medicaid changes, tariff threats, MFN pricing agreements, and PEPFAR/CDC funding cuts.
Our existing products are subject to pricing and reimbursement pressures from government agencies and other third parties, including required discounts and rebates. Successful commercialization of…
New Phase 3 trial failure (ASCENT-07) disclosed with explicit warning of potential future impairment charges to Trodelvy asset, escalating asset valuation risk.
Product Development and Supply Chain Risks We face risks in our clinical trials, including the potential for unfavorable results, delays in anticipated timelines and disruption. We are required to…
Added material geopolitical/supply chain risk: new disclosure of reliance on non-U.S. suppliers and BIOSECURE Act impact on manufacturing and clinical trials.
We may not be able to obtain materials or supplies necessary to conduct clinical trials or to manufacture and sell our products, or we may face manufacturing difficulties, delays or interruptions…
New disclosure of public scrutiny risks around pricing, supply, allocation, and IP affecting patient access and corporate reputation.
Our success depends on developing and commercializing new products or expanding the indications for existing products. If we are unable to launch commercially successful new products or new…
New ABC Safe Drug Act disclosure and AI principles add concrete regulatory risks. Reimbursement impact explicitly mentioned. Escalated specificity and scope of compliance obligations.
We are impacted by evolving laws, regulations and legislative or regulatory actions applicable to the healthcare industry. The healthcare industry is subject to various federal, state and…
REMS requirement for Yescarta/Tecartus expired June 2025, eliminating mandatory hospital certification burden. Material risk reduction for commercialization.
Product and Commercialization Risks Certain of our products subject us to additional or heightened risks. HIV We receive a substantial portion of our revenue from sales of our products for the…
ERP implementation risk removed, suggesting successful completion or project closure. Material if implementation was a significant operational concern.
The failure to successfully implement or upgrade enterprise resource planning and other information systems could adversely impact our business and results of operations. We periodically implement or…
New disclosure of FDA budget cuts and employee layoffs impairing regulatory review timelines—a material operational risk to approval processes.
Regulatory and Other Legal Risks Our operations depend on compliance with complex FDA and comparable international regulations. Failure to obtain broad approvals on a timely basis or to maintain…
Business continuity plans now described as "may be insufficient" rather than merely "in place." Escalates operational risk from preparedness to acknowledged inadequacy.
Climate change and related natural disasters, as well as legal, regulatory, or market measures to address climate change, can negatively affect our business and operations. Many of our operations and…
Gilead Sciences announced its second quarter 2026 financial results on August 4, 2026, disclosing total revenues of $7.8 billion (10% increase YoY), diluted loss per share of $(8.45), and non-GAAP diluted loss per share of $(6.75). The press release filed as Exhibit 99.1 provides comprehensive quarterly financial results including product sales by category, gross margins, operating expenses, and updated full-year 2026 guidance. This is a standard quarterly earnings release material to investors assessing the company's financial performance and outlook.
View raw filing on EDGAR →Gilead entered into an Eleventh Supplemental Indenture on May 20, 2026, governing the issuance of $3 billion in aggregate principal amount of senior notes across four series (2028, 2029, 2031, and 2034 notes) with interest rates ranging from 4.250% to 4.900%. The company intends to use net proceeds for general corporate purposes including potential acquisitions and strategic transactions.
View raw filing on EDGAR →